首页> 美国卫生研究院文献>Aging (Albany NY) >A new survival model based on ferroptosis-related genes for prognostic prediction in clear cell renal cell carcinoma
【2h】

A new survival model based on ferroptosis-related genes for prognostic prediction in clear cell renal cell carcinoma

机译:基于粘土凋亡相关基因的新生存模型在透明细胞肾细胞癌中的预后预测

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

In this study, we analyzed the clinical significance of ferroptosis-related genes (FRGs) in 32 cancer types in the GSCA database. We detected a 2-82% mutation rate among 36 FRGs. In clear cell renal cell carcinoma (ccRCC; n=539) tissues from the The Cancer Genome Atlas database, 30 of 36 FRGs were differentially expressed (up- or down-regulated) compared to normal kidney tissues (n=72). Consensus clustering analysis identified two clusters of FRGs based on similar co-expression in ccRCC tissues. We then used LASSO regression analysis to build a new survival model based on five risk-related FRGs ( and ). Receiver operating characteristic curve analysis confirmed good prognostic performance of the new survival model with an area under the curve of 0.73. High and expression and low and expression were associated with high-risk ccRCC patients. Multivariate analysis showed that risk score, age, stage, and grade were independent risk factors associated with prognosis in ccRCC. These findings demonstrate that this five risk-related FRG-based survival model accurately predicts prognosis in ccRCC patients, and suggest FRGs are potential prognostic biomarkers and therapeutic targets in several cancer types.
机译:在这项研究中,我们分析了GSCA数据库中32种癌症类型中的枯叶化相关基因(FRGS)的临床意义。我们在36毫升中检测到2-82%的突变率。在透明细胞肾细胞癌(CCRCC; n = 539)来自癌症基因组Atlas数据库的组织,与正常肾组织(n = 72)相比,36brgs的30个差异表达(上调)。共识群体分析确定了基于CCRCC组织中类似的共表达的FRGS簇。然后,我们使用了套索回归分析来构建基于五个风险相关的FRG(和)的新生存模型。接收器操作特征曲线分析证实了新的生存模型的良好预后性能,曲线下的区域为0.73。高和表达和低和表达与高风险CCRCC患者有关。多变量分析表明,风险评分,年龄,阶段和等级是与CCRCC预后相关的独立风险因素。这些发现表明,这五种风险相关的FRG的存活模型准确地预测了CCRCC患者的预后,并表明FRGS是几种癌症类型中的预后生物标志物和治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号